Propanc Biopharma, Inc. (PPCB) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
302/6 BUTLER STREET CAMBERWELL, VICTORIA, 3124 |
| State of Incorp. | DE |
| Fiscal Year End | June 30 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 3/31/2025 MRQ | 12/31/2024 MRQ | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 14,633 | 21,085 | 10,047 | 4,067 | 2,255 | 67,007 | |||
| Cash and cash equivalent | 14,633 | 21,085 | 10,047 | 4,067 | 2,255 | 67,007 | |||
| Receivables | 2,867 | 2,342 | 4,341 | 2,015 | |||||
| Prepaid expense | |||||||||
| Other current assets | |||||||||
| Other undisclosed current assets | 3,351 | 4,356 | 6,125 | 8,621 | |||||
| Total current assets: | 17,984 | 25,441 | 19,039 | 15,030 | 6,596 | 69,022 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 62,523 | 21,682 | |||||||
| Property, plant and equipment | 302 | 2,023 | 4,255 | 5,747 | |||||
| Prepaid expense | |||||||||
| Deposits noncurrent assets | 1,855 | 2,008 | 2,075 | 2,250 | 2,067 | ||||
| Deferred costs | 52,117 | 27,117 | |||||||
| Other undisclosed noncurrent assets | 6,577 | 17,799 | 40,987 | ||||||
| Total noncurrent assets: | 60,549 | 46,924 | 41,289 | 66,621 | 6,505 | 29,496 | |||
| TOTAL ASSETS: | 78,533 | 72,365 | 60,328 | 81,651 | 13,101 | 98,518 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 1,969,923 | 1,947,318 | 1,599,045 | 1,790,621 | 1,420,873 | 1,196,265 | |||
| Interest and dividends payable | ✕ | ✕ | ✕ | ✕ | 8,000 | ||||
| Employee-related liabilities | ✕ | ✕ | ✕ | ✕ | 415,799 | 418,538 | 354,109 | ||
| Accounts payable | 1,223,254 | 1,213,335 | 966,718 | 943,023 | 1,002,335 | 842,156 | |||
| Accrued liabilities | 746,669 | 733,983 | 632,327 | 423,799 | |||||
| Debt | 578,016 | 604,019 | 455,819 | 984,260 | 624,583 | 1,557,734 | |||
| Deferred compensation liability | 54,220 | 177,009 | |||||||
| Due to related parties | ✕ | ✕ | ✕ | 30,746 | 33,347 | 30,639 | |||
| Other undisclosed current liabilities | 1,607,025 | 1,241,445 | 1,103,365 | 257,354 | 947,651 | 778,296 | |||
| Total current liabilities: | 4,154,964 | 3,792,782 | 3,158,229 | 3,062,981 | 3,080,674 | 3,739,943 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation: | 42,319 | ||||||||
| Operating lease, liability | 42,319 | ||||||||
| Other undisclosed noncurrent liabilities | 82,328 | 58,642 | 19,278 | (42,319) | |||||
| Total noncurrent liabilities: | 82,328 | 58,642 | 19,278 | 42,319 | |||||
| Total liabilities: | 4,237,292 | 3,851,424 | 3,177,507 | 3,105,300 | 3,080,674 | 3,739,943 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | (4,158,759) | (3,779,059) | (3,117,179) | (3,023,649) | (3,067,573) | (3,641,425) | |||
| Common stock | 14 | 478,802 | 6,031 | 220,351 | 14,056 | 258,120 | |||
| Treasury stock, value | (46,477) | (46,477) | (46,477) | (46,477) | (46,477) | (46,477) | |||
| Additional paid in capital | 61,878,549 | 61,217,255 | 60,311,502 | 57,124,982 | 54,074,110 | 50,656,031 | |||
| Accumulated other comprehensive income | 1,491,868 | 1,269,581 | 1,294,876 | 1,234,549 | 1,085,204 | 1,267,671 | |||
| Accumulated deficit | (67,482,713) | (66,698,220) | (64,684,732) | (61,557,893) | (58,199,466) | (55,781,770) | |||
| Other undisclosed equity, attributable to parent | 1,621 | 839 | 5,000 | 5,000 | |||||
| Total equity: | (4,158,759) | (3,779,059) | (3,117,179) | (3,023,649) | (3,067,573) | (3,641,425) | |||
| TOTAL LIABILITIES AND EQUITY: | 78,533 | 72,365 | 60,328 | 81,651 | 13,101 | 98,518 | |||
Income Statement (P&L) (USD)
| 3/31/2025 TTM | 12/31/2024 TTM | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | ||
|---|---|---|---|---|---|---|---|---|
| Operating expenses | (1,184,938) | (1,536,049) | (1,776,645) | (1,990,870) | (1,812,143) | (3,494,260) | ||
| Operating loss: | (1,184,938) | (1,536,049) | (1,776,645) | (1,990,870) | (1,812,143) | (3,494,260) | ||
| Nonoperating expense | (485,345) | (413,611) | (1,013,762) | (722,194) | (327,219) | (1,381,191) | ||
| Gain (loss), foreign currency transaction, before tax | (74,816) | 22,080 | 5,885 | (42,395) | ||||
| Other nonoperating expense | (1,381,191) | |||||||
| Interest and debt expense | (9,612) | 54,565 | 25,969 | (17,503) | 50,607 | 67,123 | ||
| Loss from continuing operations before equity method investments, income taxes: | (1,679,895) | (1,895,095) | (2,764,438) | (2,730,567) | (2,088,755) | (4,808,328) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | 9,612 | (54,565) | (25,969) | 17,503 | (50,607) | |||
| Loss from continuing operations before income taxes: | (1,670,283) | (1,949,660) | (2,790,407) | (2,713,064) | (2,139,362) | (4,808,328) | ||
| Income tax benefit | 512 | 129,132 | 129,841 | 54,977 | 113,415 | 134,728 | ||
| Loss from continuing operations: | (1,669,771) | (1,820,528) | (2,660,566) | (2,658,087) | (2,025,947) | (4,673,600) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (2,658,087) | (2,025,947) | (4,673,600) | |
| Net loss: | (1,669,771) | (1,820,528) | (2,660,566) | (2,658,087) | (2,025,947) | (4,673,600) | ||
| Other undisclosed net loss attributable to parent | (391,749) | (67,123) | ||||||
| Net loss attributable to parent: | (1,669,771) | (1,820,528) | (2,660,566) | (2,658,087) | (2,417,696) | (4,740,723) | ||
| Preferred stock dividends and other adjustments | (15,800) | (192,960) | (466,273) | (700,340) | ||||
| Net loss available to common stockholders, diluted: | (1,685,571) | (2,013,488) | (3,126,839) | (3,358,427) | (2,417,696) | (4,740,723) | ||
Comprehensive Income (USD)
| 3/31/2025 TTM | 12/31/2024 TTM | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (1,669,771) | (1,820,528) | (2,660,566) | (2,658,087) | (2,025,947) | (4,673,600) | ||
| Other comprehensive income (loss) | (168,812) | (25,295) | 60,327 | 149,345 | 182,467 | |||
| Comprehensive loss: | (1,838,583) | (1,845,823) | (2,600,239) | (2,508,742) | (1,843,480) | (4,673,600) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 410,810 | (192,960) | (466,273) | (700,340) | (756,683) | 133,550 | ||
| Comprehensive loss, net of tax, attributable to parent: | (1,427,773) | (2,038,783) | (3,066,512) | (3,209,082) | (2,600,163) | (4,540,050) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.